Earnings
Altimmune Ties Alcohol-Trial Timing To Funding That Would Avoid Issuing More Shares
A December FDA meeting will help define the proposed program, while existing resources are expected to cover the MASH readout in 2029.
Altimmune (ALT) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
Earnings
A December FDA meeting will help define the proposed program, while existing resources are expected to cover the MASH readout in 2029.
SEC Filings
Liver-disease trials pushed development spending to $27.0 million, while the next FDA meeting is scheduled for December.
SEC Filings
The September 30 position came into view Tuesday, while Altimmune plans a December FDA meeting on its alcohol-use-disorder program.
SEC Filings
The draw on a $125.0 million facility also sets a minimum cash floor equal to 60% of outstanding loan principal.
SEC Filings
Former Aurinia CEO Peter Greenleaf and former Madrigal CFO Alex Howarth join the board November 2, expanding it to eleven seats.